# EDGAR Filing Document

**Accession Number:** 0001730430
**File Stem:** 0001415889-25-023587
**Filing Date:** 2025-9
**Character Count:** 9346
**Document Hash:** 8d2989e2168d18f2768bb40e8cdf9b6a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001415889-25-023587.hdr.sgml**: 20250903

**ACCESSION NUMBER**: 0001415889-25-023587

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250901

**FILED AS OF DATE**: 20250903

**DATE AS OF CHANGE**: 20250903

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Tessari Eben
- **CENTRAL INDEX KEY:** 0001867899

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38492
- **FILM NUMBER:** 251291222

**MAIL ADDRESS:**
- **STREET 1:** C/O KINIKSA PHARMACEUTICALS LTD.
- **STREET 2:** CLARENDON HOUSE, 2 CHURCH STREET
- **CITY:** HAMILTON
- **STATE:** D0
- **ZIP:** HM11

**FORMER NAME:**
- **FORMER CONFORMED NAME:** Tessan Eben
- **DATE OF NAME CHANGE:** 20210616
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kiniksa Pharmaceuticals International, plc
- **CENTRAL INDEX KEY:** 0001730430
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 23 OLD BOND STREET, FLOOR 3
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** WIS 4PZ
- **BUSINESS PHONE:** 7814319100

**MAIL ADDRESS:**
- **STREET 1:** 23 OLD BOND STREET, FLOOR 3
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** WIS 4PZ

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Kiniksa Pharmaceuticals, Ltd.
- **DATE OF NAME CHANGE:** 20180205

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Tessari Eben<br><sub>(Last) (First) (Middle)</sub><br><br>23 OLD BOND STREET, THIRD FLOOR<br><sub>(Street)</sub><br>LONDON, X0 W1S 4PZ<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-09-01 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CHIEF OPERATING OFFICER_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Kiniksa Pharmaceuticals International, plc [ KNSA ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Class A Ordinary Share | 2025-09-01 |  | M |  | 1746 | A | <sup>(1)</sup> | 41961 | D |  |
| Class A Ordinary Share | 2025-09-01 |  | M |  | 1773 | A | <sup>(1)</sup> | 43734 | D |  |
| Class A Ordinary Share | 2025-09-01 |  | M |  | 2726 | A | <sup>(1)</sup> | 46460 | D |  |
| Class A Ordinary Share | 2025-09-01 |  | F |  | 3022 | D | $33.49 | 43438 | D |  |
| Class A Ordinary Share | 2025-09-02 |  | M |  | 1964 | A | <sup>(1)</sup> | 45402 | D |  |
| Class A Ordinary Share | 2025-09-02 |  | F |  | 950 | D | $34.28 | 44452 | D |  |
| Class A Ordinary Share | 2025-09-03 |  | M<sup>(2)</sup> |  | 65 | A | $15.52 | 44517 | D |  |
| Class A Ordinary Share | 2025-09-03 |  | M<sup>(2)</sup> |  | 15026 | A | $15.50 | 59543 | D |  |
| Class A Ordinary Share | 2025-09-03 |  | S<sup>(2)</sup> |  | 15091 | D | 35.50<sup>(3)</sup> | 44452 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Share Unit | <sup>(1)</sup> | 2025-09-01 |  | A |  | 9828 |  | <sup>(4)</sup> | <sup>(4)</sup> | Class A Ordinary Share | 9828 | $0 | 9828 | D |  |
| Share Option | $33.49 | 2025-09-01 |  | A |  | 39364 |  | <sup>(5)</sup> | 2035-08-31 | Class A Ordinary Share | 39364 | $0 | 39364 | D |  |
| Restricted Share Unit | <sup>(1)</sup> | 2025-09-01 |  | M |  | 1746 |  | <sup>(6)</sup> | <sup>(6)</sup> | Class A Ordinary Share | 1746 | $0 | 5235 | D |  |
| Restricted Share Unit | <sup>(1)</sup> | 2025-09-01 |  | M |  |  | 1773 | <sup>(7)</sup> | <sup>(7)</sup> | Class A Ordinary Share | 1773 | $0 | 3545 | D |  |
| Restricted Share Unit | <sup>(1)</sup> | 2025-09-01 |  | M |  |  | 2726 | <sup>(8)</sup> | <sup>(8)</sup> | Class A Ordinary Share | 2726 | $0 | 2726 | D |  |
| Restricted Share Unit | <sup>(1)</sup> | 2025-09-02 |  | M |  |  | 1964 | <sup>(9)</sup> | <sup>(9)</sup> | Class A Ordinary Share | 1964 | $0 | 0 | D |  |
| Share Option | $15.52 | 2025-09-03 |  | M<sup>(2)</sup> |  |  | 65 | <sup>(10)</sup> | 2030-03-12 | Class A Ordinary Share | 65 | $0 | 59935 | D |  |
| Share Option | $15.50 | 2025-09-03 |  | M<sup>(2)</sup> |  |  | 15026 | <sup>(10)</sup> | 2030-09-09 | Class A Ordinary Share | 15026 | $0 | 44974 | D |  |

---

### Footnotes:

(1) Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

(2) This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

(3) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $35.50 and $35.53. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

(4) The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025.

(5) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025.

(6) The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.

(7) The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.

(8) The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.

(9) The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021.

(10) The option is fully vested and exercisable.

**Signature:** /s/ Aaron Young, Attorney-in-Fact  
**Date:** 2025-09-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**